Institute For Follicular Lymphoma Innovation
Diamond Bar, CaliforniaEIN 88-0639274
Araris Biotech Ltd the purpose of this program-related investment (PRI) is to advance the development of a breakthrough technology platform by Araris Biotech Ltd, aimed at creating innovative drug treatments for follicular lymphoma and other indolent lymphomas.
Typical award
$275,000
$231,400 to $700,960 middle range
Award count
31
Grants on record
Annual giving
$9,045,427
Tax year 2023
501(c)(3) nonprofit organizations, academic medical centers, and research institutions conducting research on follicular lymphoma and indolent lymphomas are likely eligible to apply.
LYMPHOMA RESEARCH FOUNDATION
NEW YORK
$3,282,650
2024
Lymphoma Research Foundation
New York
$3,282,650
2024
LYSARC
PIERRE BENITE
$2,336,450
2024
Lysarc
Pierre Benite
$2,336,450
2024
The Leukemia & Lymphoma Society Inc
Rye Brook
$1,211,957
2024
The Leukemia & Lymphoma Society Inc.
Rye Brook
$1,211,957
2024
THE LEUKEMIA & LYMPHOMA SOCIETY INC
RYE BROOK
$1,211,957
2024
Washington University
St Louis
$700,960
2024
See all 31 recipients
No named contacts on record for this funder.
Save this to your radar
Track this funder. Never miss a new call.
Add funders to your radar to get an email when they announce a new grant cycle, and to see who else in your world is backing organizations like yours.
See funders like this matched to your organization
You just researched one funder. Do it for the other 30,000.
Funding Findr scores 30,000 funders against your programs, size, and location. See the ones actually likely to fund you, with a match verdict and the reason in plain language. Every week.